CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

About stem cells :

Watch this dr Kurtzberg presentation ( in English from 12 minutes)

From the 20:54, Dr Joanne Kurtzberg says It’s the CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

And as I know nobody doing yet hole donor cord blood HLA matched exept Duke ( and yet in clinical trails)….

More on Dr Kurtzberg’s presentation of the good monocytes in cord blood cells:

10:38 [Referring to cord blood cells]…and about 10% are a kind of cells called the monocyte. Monocyte in cord blood is unique and it’s the cell that we think is helping patients with cp and autism. And we don’t think it’s helping because it’s engrafting in the brain or turning into neurons or turning into brain cells. We think it’s helping because it puts out chemicals that signal cells that’s already in the brain to repair damage.

human UCB (hUCB) is a complex internal environment rich in a variety of stem/progenitor cell populations, such as hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), UCB monocytes (including T regulatory cells (Tregs) and monocyte-derived suppressor cells (MDSCs)) and MSCs…etc….

UCB mononuclear/ whole blood cells in the perinatal ischemic and hypoxic brain model can reduce the inflammatory response to treat injury. To evaluate whether transplanted cells relieve neuroinflammation, there are two indicators:

(1) reduce the infiltration of CD4 þ T cells into the brain; and (2) reduce microglial activation.

all UCB cell types except EPCs have CNS immunoregulatory capacity.

Tregs and monocytes are present in the normal body at a considerable level, and are indispensable in the regulation of peripheral and central immune responses.

« Currently, the use of UCB-based interventions for CP is limited as the components of UCB are complex and possess different therapeutic mechanisms. These can be categorized by three aspects: homing and neuroregeneration, trophic factor secretion, and neuroprotective effects. »

There are several paper about cord blood CD14+ cells neuroprotective action ( CB Monocytes – CD14+ cells protect brain cells from Oxygen and Glucose Deprivation in Cortex). Even more: cord blood cells contain many neurotrophic factors, which are very important for brain regeneration.

•Brain-derived neurotrophic factor,

Nerve growth factor-

•Neurotrophin-3 –

•Neurotrophin-4 –

•Glial cell-derived neurotrophic factor –

•Cerebral dopamine neurotrophic factor –

•Mesencephalic astrocyte-derived neurotrophic factor

•Pigment epithelium-derived factor.

Latest Duke publication about CD14:

Selective percutaneous myofascial lengthening (Dr Nuzzo operation)

It’s exist study for Splm 😉

And video :

« 68 (SPML) and functional physiotherapy are an alternative to traditional open surgical lengthening and 70 physiotherapy respectively, for improving functional mobility in children with CP that have muscle

contractures and stiffness (Mansour et al2017; Mitsiokapa et al., 2010).

Here study of SPLM dr Nuzzo operation ( yes clinical study exist):

As well as study for « Improving gait and lower-limb muscle strength in children with cerebral palsy following selective percutaneous myofascial lengthening and functional physiotherapy »

What is the difference between SPLM and Microfibrilotomy or Ulzibat methode? I don’t know honestly it’s looks very similar but I am not orthopedic surgeon ok?

More about Microfibrilotomy or Ulzibat methode you can find in this article :

intravenous autologous cord blood therapy for infantile cerebral palsy

I am not sure if you will be interested in this study( the doctor (Arne Jensen )who wrote this first case treatment for boy in Germany after cardiac arrest with autologous cord blood after global hypoxic-ischemic brain damage caused by cardiac arrest followed by a quadriplegic persistent vegetative state.

But still I will post it in case if sombody will need it:


From an experimental point of view, treatment for acute hypoxic-ischemic brain damage using mononuclear cells

from human umbilical cord blood was shown to be effective, at least in the model that we and others employed. Also, insights in some important aspects regarding potential mechanisms and modes of action involved have been gathered. However, since there is virtually no information neither on the optimum amount of cells needed nor on the ideal timing of transplantation after the insult to be effective, future work should also focus on these clinically important questions.

From a clinical point of view, intravenous autologous cord blood therapy for infantile cerebral palsy is safe, however, based on the preliminary uncontrolled clinical data available, it appears only to be effective in certain cases. It is important to notice that in the majority of uncontrolled cases it was not effective. Future work and ongoing clinical trials primarily must define both the groups of brain disorders responding and the therapeutic window, in which autologous cord blood therapy may be effective, in order to avoid giving false hopes to the patients and their families. Time matters—in several respects.

The Future State of Newborn Stem Cell Banking:


Cp study 2017 ( Duke)